Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Kai Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0042-9109; OpenAlex author ID A5061508864. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 4 papers · 2024: none · 2025: 2 papers

Papers 9

  1. USP19 potentiates autophagic cell death via inhibiting mTOR pathway through deubiquitinating NEK9 in pancreatic cancer. Co-author DOI 10.1038/s41418-024-01426-y↗
  2. The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal … Co-author DOI 10.1186/s12885-025-14262-1↗
  3. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study. Co-author DOI 10.1002/cam4.5296↗
  4. Cancer-testis gene STK31 is regulated by methylation and promotes the development of pancreatic cancer. Last author DOI 10.1002/cam4.5472↗
  5. Establishment and validation of a nomogram based on coagulation parameters to predict the prognosis of pancreatic cancer. Co-author DOI 10.1186/s12885-023-10908-0↗
  6. Coagulation parameters for the differential diagnosis of pancreatic cancer in the early stage: a retrospective study. Co-author DOI 10.1186/s40001-023-01379-x↗
  7. Development and validation of a ferroptosis-related prognostic model in pancreatic cancer. Co-author DOI 10.1007/s10637-021-01114-5↗
  8. Higher miR-543 levels correlate with lower STK31 expression and longer pancreatic cancer survival. Co-author DOI 10.1002/cam4.3559↗
  9. Prognostic Nomogram for Resected Pancreatic Adenocarcinoma: A TRIPOD-Compliant Retrospective Long-Term Survival Analysis. First author DOI 10.1007/s00268-019-05325-z↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zipeng Lu · 5 shared papers, 2020–2025 · strength 0.85
  2. Kuirong Jiang · 5 shared papers, 2020–2025 · strength 0.83
  3. Yi Miao · 4 shared papers, 2020–2025 · strength 0.64
  4. Guangfu Wang · 3 shared papers, 2020–2025 · strength 0.54
  5. Yunpeng Peng · 2 shared papers, 2023 · strength 0.41
  6. Feng Guo · 2 shared papers, 2023 · strength 0.41
  7. Min Tu · 2 shared papers, 2021–2025 · strength 0.39
  8. Hao Gao Gao · 2 shared papers, 2020–2023 · strength 0.32
  9. Baobao Cai · 2 shared papers, 2020–2023 · strength 0.29
  10. Yang Feng Wu · 1 shared paper, 2025 · strength 0.26
  11. Jishu Wei · 1 shared paper, 2025 · strength 0.26
  12. Yi Miao · 1 shared paper, 2025 · strength 0.26
  13. Qianqian Wang · 1 shared paper, 2025 · strength 0.26
  14. Dong Xu · 1 shared paper, 2025 · strength 0.26
  15. Li Jiaao · 1 shared paper, 2023 · strength 0.24
  16. Wentao Gao · 2 shared papers, 2020–2021 · strength 0.23
  17. Junli Wu · 2 shared papers, 2020 · strength 0.22
  18. Lingdi Yin · 1 shared paper, 2025 · strength 0.22
  19. Shangnan Dai · 1 shared paper, 2025 · strength 0.22
  20. Kuirong Jiang · 1 shared paper, 2023 · strength 0.19
  21. Qiang Li · 1 shared paper, 2023 · strength 0.17
  22. Miao Yi · 1 shared paper, 2023 · strength 0.17
  23. Jian He · 1 shared paper, 2023 · strength 0.17
  24. Rui Zhao · 1 shared paper, 2023 · strength 0.17
  25. Kai Guo · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.